Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RECQL
REST API REST API
Homo sapiens
RECQL is differentially expressed in 321 experiments: 159 organism parts: kidney, liver, ... (157 more);, 252 disease states: normal, Huntington's disease, ... (250 more);, 114 cell types 456 cell lines 36 compound treatments and 73 other conditions.
Synonyms RecQL1, RecQ1
Orthologs SGS1 (Saccharomyces cerevisiae)   A0JN36_BOVIN (Bos taurus)   RECQL (Gallus gallus)   Recql (Mus musculus)   recql (Danio rerio)   ENSCING00000004012 (Ciona intestinalis)   Recql (Rattus norvegicus)   recql (Xenopus laevis)   RECQL (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, DNA repair, ATP-dependent helicase activity, nucleic acid binding, ATP-dependent 3'-5' DNA helicase activity, ATP binding, nucleus, ATP-dependent DNA helicase activity, DNA recombination, nucleotide binding, DNA helicase activity, DNA strand annealing activity, hydrolase activity, DNA replication, helicase activity, DNA strand renaturation
InterPro Term DNA/RNA_helicase_DEAD/DEAH_N, RQC_domain, Helicase_C, DNA_helicase_ATP-dep_RecQ, DEAD-like_helicase
UniProt Accession P46063, F5GYB7, F5H2L2, F5H4P4, F5H3W0, F8WD97, F8WA66
Search EB-eye ENSG00000004700
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-7224, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823, E-GEOD-3529
AGS
2
E-MTAB-37, E-GEOD-15460
BT-474
2
E-GEOD-3529, E-GEOD-5823
LNCaP
2
E-GEOD-14990, E-GEOD-14464
SNU16
2
E-MTAB-37, E-GEOD-15460
SW480
2
E-MTAB-37, E-GEOD-18005
450 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-TABM-34, ... (58 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3204, E-GEOD-3920, E-GEOD-26672
monocyte
2
4
E-GEOD-22373, E-MEXP-2019, E-GEOD-11755, E-MEXP-583, E-GEOD-995, ... (6 experiments)
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
CD8+ T cell
2
E-TABM-145, E-AFMX-5
germ cell
1
E-MTAB-25
monolayer
1
E-GEOD-4219
108 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-2280, ... (73 experiments)

Factor Value U/D Experiments
prostate carcinoma
2
E-MTAB-62, E-MTAB-37
mesothelioma
2
E-MTAB-37, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-62, E-GEOD-96
adenocarcinoma
2
E-MTAB-37, E-MTAB-62
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
gastric carcinoma
2
E-MTAB-37, E-GEOD-15460
246 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-7400, E-GEOD-5258, E-GEOD-15205, E-TABM-782, ... (23 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-5824, E-GEOD-412, E-TABM-782, E-GEOD-7400, E-MEXP-1269, ... (6 experiments)
lipopolysaccharide
2
E-GEOD-3720, E-MEXP-1958
non-targeting
1
E-MEXP-2218
TTA
1
E-MEXP-2590
granulocyte-colony stimulating factor
1
E-GEOD-7400
vitamin E
1
E-MEXP-1327
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-TABM-36, E-GEOD-860, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-22541, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-TABM-127, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (36 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-980, E-GEOD-17400

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-26495, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Processing time: 0.359 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM